Having demonstrated that FHVH1 and FHVH3 bind different CD5 antigenic epitopes, we hypothesized that the use of FHVH1 and FHVH3 in tandem may both enhance the efficacy and reduce the risk of tumor escape caused by antigenic mutations. Here, CD5 is linked to neoplasm.